• Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 163

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Pα+ Psychedelic Bulletin #211: AbbVie Officially Enters Psychedelics; atai-Beckley’s 5-MeO-DMT Scores Breakthrough Therapy Designation; California Bill Signed

Q3’25 Investor Survey: What are Investors Most Concerned About?

A European Model: Robert Schoevers on the Continent’s Growing Psychedelic Research Agenda

Psychedelic Insights Playground

Brad Adams PhD – LAMPS

Small Pharma to Participate in the H.C. Wainwright 1st Annual Mental...

Field Trip Health Ltd. Schedules Fiscal Fourth Quarter and Full Year...

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine...

Bright Minds Biosciences Establishes Scientific Advisory Board, Comprising Five Preeminent Physicians...

Bright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet...

Numinus Applies for International Patent Filing of Psychedelics Production Process

Small Pharma Reports Highlights for the Fiscal Year Ended February 28,...

Field Trip Health Ltd. Announces Increased Participation in Arrangement Financing and...

Mindmed Announces Voting Results for Annual General and Special Meeting

GH Research Reports First Quarter 2022 Financial Results and Provides Business...

1...162163164...300Page 163 of 300

EDITOR PICKS

Pα+ Psychedelic Bulletin #211: AbbVie Officially Enters Psychedelics; atai-Beckley’s 5-MeO-DMT Scores...

Q3’25 Investor Survey: What are Investors Most Concerned About?

A European Model: Robert Schoevers on the Continent’s Growing Psychedelic Research...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    ©